Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Community-onset (CO) candidemia, defined as a positive blood culture taken at or within 2 days of hospital admission, represents a distinct clinical entity associated with substantial morbidity and mortality. Reference MIC results from the SENTRY Antimicrobial Surveillance Program (2008-2009) were analyzed to compare the antifungal resistance patterns and species distributions from patients with CO and nosocomial bloodstream infections (BSI) in 79 medical centers. Among 1,354 episodes of BSI, 494 (36.5%) were classified as CO and 860 (63.5%) as nosocomial in origin. More than 95% of the isolates from both BSI types were contributed by Candida albicans (48.4%), C. glabrata (18.2%), C. parapsilosis (17.1%), C. tropicalis (10.6%), and C. krusei (2.0%). C. albicans was more common in CO BSI (51.0%) than nosocomial BSI (46.9%), whereas C. parapsilosis and C. krusei were more common in nosocomial BSIs (18.1 and 2.7%, respectively) than in CO BSIs (15.4 and 0.8%, respectively). C. glabrata and C. tropicalis were comparable in both CO (18.4 and 10.5%, respectively) and nosocomial (18.1 and 10.6%, respectively) episodes. Resistance to azoles (fluconazole, posaconazole, and voriconazole) and echinocandins (anidulafungin, caspofungin, and micafungin) was uncommon (<5%) in CO BSI using recently established Clinical and Laboratory Standards Institute breakpoint criteria. Resistance to echinocandins (anidulafungin [3.8%], caspofungin [5.1%], and micafungin [3.2%]) and azoles (fluconazole [7.7%], posaconazole [5.1%], and voriconazole [6.4%]) was most prevalent among nosocomial BSI isolates of C. glabrata . CO candidemia is not uncommon and appears to be increasing worldwide due to changing health care practices. Although resistance to the azoles and echinocandins remains uncommon among CO isolates, we demonstrate the emergence of nosocomial occurrences of C. glabrata expressing resistance to both monitored classes of antifungal agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Species and drug- resistance patterns are known to vary substantially by geography, facility, and even among units within the same facility [24, 25].”
From Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018. (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With respect to CLSI clinical breakpoints, fluconazole resistance, defined as MIC values ≥8 mg/L for C. albicans, has been reported overall to be as high as 3.5%.43–48”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“Second, the increased incidence of invasive candidiasis caused by non-albicans Candida (NAC) species, such as Candida glabrata, Candida tropicalis, Candida krusei or Candida parapsilosis, has been a major concern [13], [14], because these infections are often associated with higher mortality and antifungal resistance than those caused by C. albicans [15], [16].”
From In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections (2014) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 2×
“Hajjeh et al. (17) have shown that in 1998 through 2000, only 36% of Candida BSIs occurred in the ICU, whereas 28% were community onset (CO), an increase of almost 10% above that reported in 1992 and 1994 (19).”
ResultEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“Although much of the literature concerning IC has focused on nosocomial (NOS) bloodstream infections (BSI), especially those occurring in the intensive care unit (ICU) (3, 12, 13, 25, 27, 49), an increasing incidence of IC overall (35, 50), combined with data from the National Nosocomial Infection System survey, which…”
ResultSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 2×
“parapsilosis should be noted in light of the recommendation of the Infectious Diseases Society of America that infection with this species should be treated with either an azole or amphotericin B (lipid formulation) rather than an echinocandin (30).”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Weinstein, M. P., Towns, M. L., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Barth Reller, L. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,228
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171 · cited 1×
“It is now evident that a delay in initiating antifungal therapy in the critically ill patient is associated with compromised outcomes (an increase in mortality of 8% for each hour in which appropriate therapy is delayed), excessive costs of hospitalization, and potentially devastating complications such as endocarditi…”
BackgroundEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationEpidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Blumberg, H. M., Jarvis, W. R., Soucie, J. M., Edwards, J. E., Patterson, J. E., Pfaller, M. A., Rangel‐Frausto, M. S., Rinaldi, M. G., Saiman, L., Wiblin, R. T., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/321811 · Cited by 661
Self-citationTrick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Cited by
Items 101–200 of 243
Jabeen, K., Kumar, H., Farooqi, J. Q., Mehboob, R., Brandt, M. E., & Zafar, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.02432-15 · Cited by 23
Asadzadeh, M., Alanazi, A. F., Ahmad, S., Al‐Sweih, N., & Khan, Z. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223920 · Cited by 25
Liu, Z., Basso, P., Hossain, S., Liston, S. D., Robbins, N., Whitesell, L., Noble, S. M., & Cowen, L. E. (2023) · Nature Communications · doi:10.1038/s41467-023-40209-w · Cited by 22
“Among these, Candida albicans is one of the most frequent causes of invasive infection, with systemic candidiasis causing considerable morbidity and driving mortality rates as high as 40% despite treatment 7 .”
Fungemias en hospitales de la Ciudad de Buenos Aires, Argentina
Moral, L. L., Tiraboschi, I. N., Schijman, M., Bianchi, M., Guelfand, L. I., & Cataldi, S. (2011) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2011.11.001 · Cited by 24
Borah, S., Shivarathri, R., Srivastava, V. K., Ferrari, S., Sanglard, D., & Kaur, R. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02786-14 · Cited by 23
CAND-LO 2014–15 study: changing epidemiology of candidemia in Lombardy (Italy)
Prigitano, A., Cavanna, C., Passera, M., Ossi, C. M., Sala, E., Lombardi, G., Grancini, A., Luca, C. D., Bramati, S., Gelmi, M., et al. (2016) · Infection · doi:10.1007/s15010-016-0951-6 · Cited by 23
Gold, J. A. W., Seagle, E. E., Nadle, J., Barter, D. M., Czaja, C. A., Johnston, H., Farley, M. M., Thomas, S., Harrison, L. H., Fischer, J., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab512 · Cited by 20
Echinocandin-Resistant Candida: Molecular Methods and Phenotypes
Perlin, D. S. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0054-x · Cited by 22
Won, E. J., Choi, M. J., Jeong, S. H., Kim, D., Shin, K. S., Shin, J. H., Kim, Y. R., Kim, H. S., Kim, Y. A., Uh, Y., et al. (2022) · Journal of Fungi · doi:10.3390/jof8100996 · Cited by 24
Raber, H. F., Sejfijaj, J., Kissmann, A., Wittgens, A., González-García, M., Alba, A., Vázquez, A. A., Morales-Vicente, F., Perez‐Erviti, J. A., Kubiczek, D. H., et al. (2021) · Pathogens · doi:10.3390/pathogens10040496 · Cited by 21
Neves, A., Cartágenes-Pinto, A. C., Rocha, D. A. S., de Sá, L. F. R., Junqueira, M. D. L., & Ferreira‐Pereira, A. (2015) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201520140717 · Cited by 27
Orasch, C., Mertz, D., Garbino, J., van Delden, C., Emonet, S., Schrenzel, J., Zimmerli, S., Damonti, L., Mühlethaler, K., Imhof, A., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2017.12.018 · Cited by 19
Șular, F.-L., Székely, E., Cristea, V. C., & Dobreanu, M. (2018) · Mycopathologia · doi:10.1007/s11046-018-0293-2 · Cited by 21
Rae, N., Kenny, C. C., & Muldoon, E. G. (2018) · Mycoses · doi:10.1111/myc.12874 · Cited by 19
Toutounji, M., Tokajian, S. T., & Khalaf, R. A. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.02.008 · Cited by 19
Romeo, O., Delfino, D., Costanzo, B., Cascio, A., & Criseo, G. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.12.002 · Cited by 18
Transcriptome profile of the murine macrophage cell response to Candida parapsilosis
Németh, T., Tóth, A., Hamari, Z., Falus, A., Éder, K., Vágvölgyi, C., Guimaraes, A. J., Nosanchuk, J. D., & Gácser, A. (2014) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2014.01.006 · Cited by 19
Niimi, K., Woods, M. A., Maki, K., Nakayama, H., Hatakenaka, K., Chibana, H., Ikeda, F., Ueno, K., Niimi, M., Cannon, R. D., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks112 · Cited by 18
Evaluación de la espectrometría de masas en la identificación de levaduras de interés clínico
Galán‐Sánchez, F., García-Agudo, L., Guerrero, I., Marín, P., García-Tapia, A. M., García-Martos, P., & Rodríguez‐Iglesias, M. (2014) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2014.10.003 · Cited by 23
Identification of Components of the SUMOylation Machinery in Candida glabrata
Gujjula, R., Veeraiah, S., Kumar, K., Thakur, S. S., Mishra, K., & Kaur, R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.706044 · Cited by 20
Biofilm-formation capability depends on environmental oxygen concentrations in Candida species
Koshikawa, T., Abe, M., Nagi, M., Miyazaki, Y., & Takemura, H. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.01.010 · Cited by 17
Srisurapanont, K., Lerttiendamrong, B., Meejun, T., Thanakitcharu, J., Manothummetha, K., Thongkam, A., Chuleerarux, N., Sanguankeo, A., Li, L. X., Leksuwankun, S., et al. (2024) · Mycoses · doi:10.1111/myc.13798 · Cited by 17
Nosocomial Candida parapsilosis candidaemia: risk factors, antifungal susceptibility and outcome
Hirai, Y., Asahata, S., Ainoda, Y., Goto, A., Fujita, T., & Totsuka, K. (2014) · Journal of Hospital Infection · doi:10.1016/j.jhin.2014.02.006 · Cited by 19
Pathogenic Candida species differ in the ability to grow at limiting potassium concentrations
Hušeková, B., Elicharová, H., & Sychrová, H. (2016) · Canadian Journal of Microbiology · doi:10.1139/cjm-2015-0766 · Cited by 18
Antifungal activity of silver nanoparticles and clotrimazole against Candida spp.
Meneses, M. L., Recalde, M., Martín, P. L., & Pardo, A. G. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e18719 · Cited by 20
Sensitive and rapid RT-qPCR quantification of pathogenic Candida species in human blood
Ogata, K., Matsuda, K., Tsuji, H., & Nomoto, K. (2015) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2015.07.021 · Cited by 19
Tortorano, A. M., Prigitano, A., Dho, G., Grancini, A., Passera, M., & for the ECMM-FIMUA Study Group (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.037895-0 · Cited by 18
Kaneva, I. N., Sudbery, I. M., Dickman, M. J., & Sudbery, P. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-42530-1 · Cited by 16
In vitro susceptibility and molecular characterization of Candida spp. from candidemic patients
Herkert, P. F., Gomes, R. R., Muro, M. D., Pinheiro, R. L., Fornari, G., Vicente, V. A., & Queiroz‐Telles, F. (2014) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2014.07.007 · Cited by 15
Alvarez-Rueda, N., Rouges, C., Touahri, A., Misme‐Aucouturier, B., Albassier, M., & Pape, P. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-63344-6 · Cited by 17
Rodrigues, C. F., Correia, A., Vilanova, M., & Henriques, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020142 · Cited by 16
Epidémiologie des candidoses invasives
Toubas, D. (2013) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(13)71944-0 · Cited by 19
Wang, Y., McGuire, T., Hollingworth, S., Dong, Y., & van Driel, M. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.10.016 · Cited by 15
Prevalent Drug Resistance Among Oral Yeasts from Asymptomatic Patients in Hainan, China
Wu, J., Guo, H., Yi, G., Zhou, L., He, X., Huang, X., Wang, H., WeiLing, X., & Xu, J. (2014) · Mycopathologia · doi:10.1007/s11046-014-9747-3 · Cited by 14
Chakraborti, S., Ramakrishnan, G., & Srinivasan, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00016-x · Cited by 16
Wu, J., Gan, C., Li, J., Liu, Y., Chen, Z., Zhang, Y., Yi, G., Sui, J., & Xu, J. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s316368 · Cited by 14
Ahn, H., Lee, R., Cho, S., & Lee, D. (2022) · Blood Research · doi:10.5045/br.2022.2022036 · Cited by 14
Rosenblatt, J. S., Reitzel, R. A., Vargas‐Cruz, N., Chaftari, A., Hachem, R. Y., & RAAD, I. I. (2017) · Journal of Fungi · doi:10.3390/jof3010007 · Cited by 14
The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus
Ostrosky-Zeichner, L. L., & Andes, D. R. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix239 · Cited by 14
Aslani, N., Shokohi, T., Ataollahi, M. R., Ansari, S., Gholampour, Y., Jeihooni, A. K., & Afsarian, M. H. (2019) · Current Medical Mycology · doi:10.18502/cmm.5.4.1949 · Cited by 15
Nacsa-Farkas, E., Kerekes, E., Kerekes, E. B., Krisch, J., Popescu, R., Vlad, D. C., Ivan, P., & Vágvölgyi, C. (2014) · SZTE Publicatio Repozitórium (University of Szeged) · Cited by 17
Mauri, C., Consonni, A., Briozzo, E., Giubbi, C., Meroni, E., Tonolo, S., & Luzzaro, F. (2023) · Antibiotics · doi:10.3390/antibiotics12081247 · Cited by 11
Li, W., Hu, Y., Li, F., Shi, L.-N., Shao, H., Huang, M., Wang, Y., Han, D., Liao, H., Chun-fang, M., et al. (2015) · Mycopathologia · doi:10.1007/s11046-015-9858-5 · Cited by 12
Genetic diversity and antifungal susceptibility of Candida albicans isolated from Iranian patients
Sharifynia, S., Rezaie, S., Mohamadnia, A., Mortezaee, V., Hadian, A., & Seyedmousavi, S. (2018) · Medical Mycology · doi:10.1093/mmy/myy016 · Cited by 12
Candida parapsilosis endocarditis. Report of cases and review of the literature
Ιωάννου, Π., Volosyraki, M., Mavrikaki, V., Papakitsou, I., Mathioudaki, A., Samonis, G., & Kofteridis, D. P. (2020) · GERMS · doi:10.18683/germs.2020.1214 · Cited by 13
Marcos-Zambrano, L. J., Escribano, P., Bouza, E., & Guinea, J. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.06.003 · Cited by 13
Franiczek, R., Gleńsk, M., Krzyżanowska, B., & Włodarczyk, M. (2015) · Medical Mycology · doi:10.1093/mmy/myv035 · Cited by 12
Mendes, J. F., Gonçalves, C. L., Ferreira, G. F., Esteves, I. A., de Freitas, C. H., Villarreal, J. P. V., de Mello, J. R. B., Meireles, M. C. A., & Nascente, P. D. S. (2017) · Brazilian Journal of Biology · doi:10.1590/1519-6984.04916 · Cited by 16
Hady, R. E., Fattouh, N., Finianos, M., Bitar, I., Fakih, T., Husni, R., & Khalaf, R. A. (2025) · Scientific Reports · doi:10.1038/s41598-024-84535-5 · Cited by 11
Abuelizz, H. A., Bakheit, A. H. H., Al-Agamy, M. H., Rashid, H., Mostafa, G. A. E., & Al‐Salahi, R. A. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.04.012 · Cited by 10
Kovács, F., Balla, N., Bozó, A., Harmath, A., Jakab, Á., Tóth, Z., Nagy, F., Majoros, L., & Kovács, R. (2024) · Mycoses · doi:10.1111/myc.13727 · Cited by 10
Rattani, S., Farooqi, J. Q., Hussain, A. S., & Jabeen, K. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003161 · Cited by 10
Kahramanmaras Afsin Devlet Hastanesi, I. H. V. K. M. K., Kolak, C. C., Daloğlu, A. E., Özhak, B., Öğünç, D., & Günseren, F. (2020) · Klimik Dergisi/Klimik Journal · doi:10.5152/kd.2019.71 · Cited by 10
Norimatsu, Y., Morii, D., Kogure, A., Hamanaka, T., Kuwano, Y., Yokozawa, T., & Oda, T. (2017) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2017.03.002 · Cited by 8
Walter, J.-C., Kissmann, A., Gruber, D., Alpízar-Pedraza, D., Martell-Huguet, E. M., Preising, N., Rodríguez, A., Ständker, L., Kleber, C., Knoll, W., et al. (2025) · Biomolecules · doi:10.3390/biom15030322 · Cited by 9
Huyke, J., Martin, R., Walther, G., Weber, M., Kaerger, K., Bougnoux, M., Elias, J., & Kurzai, O. (2015) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2015.08.027 · Cited by 8
Queiroz-Aaltonen, I. R. D. O., de Melo-Neto, M. F., da Fonseca, L. A. V., Silva, D. M. W., & Maranhão, F. C. D. A. (2021) · Brazilian Archives of Biology and Technology · doi:10.1590/1678-4324-2021200763 · Cited by 8
Chow, E. W. L., Song, Y., Wang, H., Xu, X., Gao, J., & Wang, J. (2024) · Molecular Microbiology · doi:10.1111/mmi.15229 · Cited by 8
Shafeeq, S., Pannanusorn, S., Elsharabasy, Y., Ramírez-Zavala, B., Morschhäuser, J., & Römling, U. (2019) · FEMS Yeast Research · doi:10.1093/femsyr/foz057 · Cited by 11
Ghezzi, M. C., Brunetti, G., Visconti, V. V., Giordano, A., & Raponi, G. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000505 · Cited by 7
Introduction to Medical Mycology
Chakrabarti, A., & Sethuraman, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-64113-3_1 · Cited by 8
Clinical Syndromes: Candida and Candidosis
Ruhnke, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92300-0_4 · Cited by 8
Candida parapsilosiscomplex induces local inflammatory cytokines in immunocompetent mice
Treviño‐Rangel, R. D. J., González, G. M., Martínez-Castilla, A. M., García‐Juárez, J., Robledo-Leal, E., González‐González, J. G., & Rosas-Taraco, A. G. (2015) · Medical Mycology · doi:10.1093/mmy/myv021 · Cited by 8
Santos, F. R. D. S., Andrade, J. T., de Sousa, C. D. F., Fernandes, J. S., Carmo, L. F. D., Araújo, M. G. D. F., Ferreira, J. M. S., & Villar, J. A. F. P. (2019) · Medicinal Chemistry · doi:10.2174/1573406414666180730111954 · Cited by 7
Candida Pathogenicity and Alternative Therapeutic Strategies
Manzoor, N. (2019) · Springer eBooks · doi:10.1007/978-981-32-9449-3_7 · Cited by 7
Salas, V., Pastor, F., Calvo, E., Mayayo, E., Quindós, G., Carrillo, A. J., & Guarro, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00500-11 · Cited by 7
Chávez, J. A. C., García-Bouchot, G., García-Gutiérrez, N., Vergara‐Castañeda, H. A., Nava, R., Luna‐Bárcenas, G., Elizalde-Peña, E. A., Naranjo, E. U. E., Landeros, F., Rojas‐Avelizapa, N. G., et al. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230303145653 · Cited by 6
Sanglard, D. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0055-9 · Cited by 7
Opportunistic Fungal Invasion in COVID-19 Pandemic: A Critical Review in Diagnosis and Management
Sharma, A., Bano, G., Malik, A., Rasool, Y., Manzar, S., Singh, T., & Maity, M. K. (2023) · Avicenna Journal of Medicine · doi:10.1055/s-0043-1770921 · Cited by 7
Anti-Candida activity of antimicrobial impregnated central venous catheters
Cobrado, L., Silva-Dias, A., Azevedo, M. M., & Rodrigues, A. G. (2017) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-017-0269-x · Cited by 8
Partridge and embryonated partridge egg as new preclinical models for candidiasis
Tavakkoli, H., Khosravi, A., Sharifi, I., Salari, Z., Salarkia, E., Kheirandish, R., Dehghantalebi, K., Jajarmi, M., Mosallanejad, S. S., Dabiri, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81592-y · Cited by 6
Cai, G., & Zhang, Z. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01617-25 · Cited by 5
Prusty, J. S., Kumar, A., & Kumar, A. (2024) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2024.2418125 · Cited by 8
Samaranayake, D., Atencio, D. P., Morse, R. H., Wade, J. T., Chaturvedi, V. P., & Hanes, S. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059094 · Cited by 5
Deconinck, L., Meybeck, A., Pradier, M., Patoz, P., Melliez, H., & Senneville, E. (2016) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-016-0129-1 · Cited by 5
Salas, V., Pastor, F. J., Capilla, J., Sutton, D. A., Mayayo, E., Fothergill, A. W., Rinaldi, M. G., & Guarro, J. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.05.011 · Cited by 4
Castillo-Cruz, J., Palacios-Barreto, S., Mosso-Pani, M. A., Serna-Pérez, A. B., Rodríguez-Tovar, A. V., Serafín‐López, J., Castrejón-Jiménez, N. S., & García‐Pérez, B. E. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107479 · Cited by 4
Murat, J., Lebeau, B., Chumpitazi, B. F. F., Cornet, M., Maubon, D., Faure, O., Quésada, J.-L., Thiébaut, A., Timsit, J., & Pelloux, H. (2012) · Mycoses · doi:10.1111/j.1439-0507.2012.02200.x · Cited by 4
Pilmis, B., Yang, Z., Lanternier, F., & Lortholary, O. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00049-6 · Cited by 6
Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins
Pfaller, M. A., Diekema, D. J., Castanheira, M., & Jones, R. N. (2011) · Current Fungal Infection Reports · doi:10.1007/s12281-011-0053-y · Cited by 4
Self-citationHost-Fungal Interactions: Pathogenicity versus Immunity
Tavanti, A., Naglik, J. R., & Osherov, N. (2012) · International Journal of Microbiology · doi:10.1155/2012/562480 · Cited by 5
de Souza, Â. C., Pereira, D. C., Barth, P. O., Roesch, E. W., Lutz, L., Aquino, V. R., & Goldani, L. Z. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116271 · Cited by 3
Kovács, F., Harmath, A., Balázsi, D., Forgács, L., Ragyák, Á., Balla, N., Tóth, Z., Bozó, A., Borman, A. M., Majoros, L., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.02686-25 · Cited by 3
Immunomodulatory Agents as Adjunctive Therapy for the Treatment of Resistant Candida Species
Beyda, N. D., Regen, S., Lewis, R. E., & Garey, K. W. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-013-0132-3 · Cited by 3
Ishida, K., Yamaguchi, M. U., Ueda‐Nakamura, T., Filho, B. P. D., Yamada‐Ogatta, S. F., & Nakamura, C. V. (2013) · Semina Ciências Biológicas e da Saúde · doi:10.5433/1679-0367.2013v34n2p205 · Cited by 3
Antifungal Susceptibility of Oral Candida Species Isolated from Patients with Thalassemia Major
El-Shokry, M. (2017) · Journal of Bacteriology & Mycology Open Access · doi:10.15406/jbmoa.2017.05.00160 · Cited by 3
Turan, D., & Aksaray, S. (2022) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20229709 · Cited by 5
Impact of the Disk Diffusion Test on Fluconazole De-Escalation in Patients with Candidemia
Tantasuwan, S., Chongtrakool, P., Waesamaae, A., & Chayakulkeeree, M. (2022) · Journal of Fungi · doi:10.3390/jof8111185 · Cited by 4
Human yeast-specific CD8 T lymphocytes show a nonclassical effector molecule profile
Breinig, T., Scheller, N., Glombitza, B., Breinig, F., & Meyerhans, A. (2011) · Medical Microbiology and Immunology · doi:10.1007/s00430-011-0213-2 · Cited by 3
Antibiofilm effect of Tucum (Astrocaryum sp.) endosperm against Candida albicans
Ana, C. A. U. R. D. M., Ana, L. U. C. M. D. S., Rainey, O. V., Filipe, A. M. A. U. J., & de Lucena, J. M. V. M. (2016) · African Journal of Microbiology Research · doi:10.5897/ajmr2015.7829 · Cited by 3
Yeast Infections After Solid Organ Transplantation
McCarty, T. P., & Pappas, P. G. (2016) · Springer eBooks · doi:10.1007/978-3-319-28797-3_38 · Cited by 3
Immunological Identification of Fungal Species
Nogueira, F., Istel, F., Pereira, L., Tscherner, M., & Kuchler, K. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6515-1_20 · Cited by 3
Epidemiology of Bloodstream Infections
McMullen, A. R., Wilen, C. B., & Burnham, C. D. (2017) · doi:10.1128/9781555819811.ch9 · Cited by 4
Batista, C. S. P., Rivera, A., Alvarez Albarran, M. T., Rubio, M., Belen-Figas, I., Lopez-Querol, C., Miró, E., Navarro, F., & Sanchez-Reus, F. (2025) · Journal of Fungi · doi:10.3390/jof11110808 · Cited by 2
“Community-onset fungemia, characterized by a positive fungal blood culture obtained within 48 h of hospital admission, is an important clinical condition linked with significant morbidity and mortality [1,2].”
Tam, W. Y. J., Tsui, C. K. M., Beardsley, J., & Barrs, V. R. (2026) · Fungal Biology Reviews · doi:10.1016/j.fbr.2026.100501 · Cited by 2
Chen, Y.-C., Ho, M., Chao, W., & Chang, C. (2023) · Epidemiology and Infection · doi:10.1017/s0950268823000894 · Cited by 2
Karvar, Ş., & Delıalıoğlu, N. (2023) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.20239703 · Cited by 2
Pasman, R., Zhang, J., Zaat, S. A. J., Brul, S., & Krom, B. P. (2024) · Applied and Environmental Microbiology · doi:10.1128/aem.00360-24 · Cited by 3
Prevalence and Antifungal Susceptibilities of Candida spp from a South Indian Tertiary Care Hospital
Rajgopal, S. K. (2017) · International Journal of Medical Research and Review · doi:10.17511/ijmrr.2017.i02.01 · Cited by 3
Rola, A., Potok, P., Mos, M., Gumienna‐Kontecka, E., & Potocki, S. (2022) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.2c02080 · Cited by 3
Metadata
- Authors
- Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M.
- Affiliations
- JMI Laboratories (US)
- Tufts University (US)
- Corresponding author
- Castanheira, Mariana
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-02
- Volume
- 55
- Issue
- 2
- Pages
- 561-566
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3028787
- OpenAlex
- W2103765663
- Cited by
- 238
- References
- 49
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 9 · 2023: 9 · 2022: 9 · 2021: 12 · 2020: 7 · 2019: 25 · 2018: 11 · 2017: 18 · 2016: 24 · 2015: 24 · 2014: 20 · 2013: 20 · 2012: 20
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- candidemia, nosocomial bloodstream infection, Candida species distribution, antifungal resistance, echinocandin resistance, azole resistance, Candida glabrata, Candida albicans, Candida parapsilosis, Candida tropicalis, Candida krusei, SENTRY Antimicrobial Surveillance Program, MIC breakpoints, fluconazole
- MeSH terms
- Antifungal Agents, Azoles, Candida, Candidiasis, Cross Infection, Humans, Microbial Sensitivity Tests, Population Surveillance, Species Specificity, Global Health, Community-Acquired Infections, Drug Resistance, Fungal, Echinocandins, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.